Still a boring market in terms of news. The sector appears to have successfully defended the bottom end of its range but one could argue it done so simply by.
The sector struggled yesterday and it still looks like testing the bottom on the range is possible. Perhaps the China tariffs news cleared the market a little and we might.
Last week, Xenon pharmaceuticals (XENE) passed one of the most important tests in the stock market, where the share price closed on Friday at $14.05, above the $14.03 resistance line,.
Not a great start to the week in terms of trading as it looks like we are set to retest the bottom on the range (yet again). As long as.
Sarepta (SRPT) had a great run last week, a kick off following MS fireside chat, closing at $152.76 the highest “close” since June 21st (highest 52W close 06/20 was $153.69).
We are finally getting a broad snap back rally but it needs to be more than a simple morning rally that is faded as the day goes along. If this.
The sector is certainly struggling and its inability to generate any consistent buying interest after the sell-off is certainly worrisome. All of that being said there are so many names.
While we have another snoozer of a day in biotech land, it does provide some insight into the trading bias of the sector and it remains negative. You would think.
The hurricane thankfully missed us, so back in the office. The sector had a rough day yesterday but it only took us to the area that should act as new.
Another slow start to the week. Sometimes there are expectations for deals after long weekends but the sector continues to disappoint in terms of M&A. Given how important M&A was.
The range finally seems broken and pretty decisively to the upside. The sector is not just moving higher but it is outperforming the broader market on a relative basis. Given.
Today morning, Xenon Pharmaceutical (XENE) reported positive data from its XEN1101 Phase 1b transcranial magnetic stimulation (TMS) study. (LINK) XEN1101 Demonstrates Statistically Significant Reduction in Corticospinal and Cortical Excitability as.
We got off to a good start yesterday and there is perhaps some early follow through this morning but not much. We are inching closer to the upper end of.
The snoozer of a week continues with the sector still chopping in its range. Perhaps next week we wake up a little but odds are we are stuck in this.
*** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.***.
Up, down, up, down, and repeat. Yesterday was green so today is most likely to be red. While it is difficult to discern a trend in such a low volume,.
A pretty weak open for the sector but again this is nothing more than low volume chop as I see it. Unless it breaks below 113 on the IBB and.
BELLUS Health (BLU.TO) (BLUSF) is a biopharmaceutical development company based in Quebec, Canada, its pipeline includes several partnered clinical-stage drug development programs, but the company’s lead drug candidate is BLU-5937.
The chop continues and I suspect this week will be no different. There is not any news to start the week that would excite or disappoint, which means the previous.
The chop continues. I just do not see anything definitive in either direction and am coming around to the belief that we are not going to see anything definitive soon..
Follow up to my previous report “XENE – Epilepsy and Advocacy Under the New FDA” (Link) XENE released their Q2 earning report and hosted a conference call and webcast to.
We are not quite getting the clarity to the upside but there is nothing to indicate that the sector is about to break to the downside. It seems like the.
Xenon Pharmaceuticals (XENE) is a clinical stage biopharmaceutical company focusing on discovering and developing innovative therapeutics for neurological disorders. XENE has an extensive knowledge of human genetics and diseases caused.
A slow start to the week in which there are a lot of earnings calls but likely nothing to change the course of the sector. That has already been set.